Newton biotech says drug targeting cell's energy center shows promise

A Newton biotech says it has moved one step closer to developing the first treatment for rare genetic diseases of the mitochondria — the powerhouses of the cell that create 90 percent of the human body’s energy. Privately held Stealth BioTherapeutics on Thursday unveiled what it characterized as positive data from a Phase 2 study of its potential treatment for "mitochondrial myopathy," muscle weakness caused by a broad cla ss of diseases. The 50-employee company, which has raised around $200…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news